Compare ASLE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | SNY |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 107.3B |
| IPO Year | 2018 | N/A |
| Metric | ASLE | SNY |
|---|---|---|
| Price | $6.15 | $46.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $58.00 |
| AVG Volume (30 Days) | 290.8K | ★ 3.7M |
| Earning Date | 03-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.43% |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $335,286,000.00 | N/A |
| Revenue This Year | $23.41 | $3.01 |
| Revenue Next Year | $6.80 | $5.80 |
| P/E Ratio | $34.44 | ★ $6.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $43.32 |
| 52 Week High | $9.08 | $55.77 |
| Indicator | ASLE | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 30.61 | 58.78 |
| Support Level | $6.05 | $45.20 |
| Resistance Level | $6.17 | $48.97 |
| Average True Range (ATR) | 0.15 | 0.76 |
| MACD | -0.00 | 0.37 |
| Stochastic Oscillator | 12.35 | 77.94 |
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.